AR122339A1 - Métodos y composiciones para el tratamiento y la prevención de la diabetes tipo 1 - Google Patents
Métodos y composiciones para el tratamiento y la prevención de la diabetes tipo 1Info
- Publication number
- AR122339A1 AR122339A1 ARP200103323A ARP200103323A AR122339A1 AR 122339 A1 AR122339 A1 AR 122339A1 AR P200103323 A ARP200103323 A AR P200103323A AR P200103323 A ARP200103323 A AR P200103323A AR 122339 A1 AR122339 A1 AR 122339A1
- Authority
- AR
- Argentina
- Prior art keywords
- diabetes
- type
- subject
- insulin
- delaying
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
La divulgación proporciona métodos para prevenir o tratar la diabetes tipo 1 en un sujeto mamífero, reducir los factores de riesgo asociados con la diabetes tipo 1 y/o reducir la probabilidad o la gravedad de la diabetes tipo 1. También se proporciona un método para atenuar una respuesta antigénica en un mamífero a al menos un antígeno relacionado con la diabetes tipo 1. Reivindicación 1: Un método para retrasar el inicio de la hiperglucemia, retrasar el inicio de la diabetes tipo 1 o disminuir la probabilidad de padecer diabetes tipo 1 en un sujeto que lo necesita, que comprende: la administración sublingual de una cantidad terapéuticamente eficaz de un péptido relacionado con la insulina al sujeto. Reivindicación 37: Una composición que comprende: un péptido relacionado con la insulina; y un vehículo acuoso farmacéuticamente aceptable, que comprende al menos aproximadamente 30% en volumen de glicerol.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962944503P | 2019-12-06 | 2019-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR122339A1 true AR122339A1 (es) | 2022-09-07 |
Family
ID=76222225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200103323A AR122339A1 (es) | 2019-12-06 | 2020-11-30 | Métodos y composiciones para el tratamiento y la prevención de la diabetes tipo 1 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230018324A1 (es) |
| EP (1) | EP4069278A4 (es) |
| JP (1) | JP2023505190A (es) |
| CN (1) | CN115151273A (es) |
| AR (1) | AR122339A1 (es) |
| AU (1) | AU2020398147A1 (es) |
| CA (1) | CA3159054A1 (es) |
| TW (1) | TW202133876A (es) |
| WO (1) | WO2021113136A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3193994A1 (en) * | 2020-10-08 | 2022-04-14 | Mary S. MORRIS | Methods and compositions for the treatment and prevention of type 1 diabetes |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA004631B1 (ru) * | 1999-12-16 | 2004-06-24 | Эли Лилли Энд Компани | Полипептидные композиции, обладающие повышенной стабильностью |
| EP1578432A4 (en) * | 2002-10-03 | 2008-07-30 | Epimmune Inc | HLA BINDING PEPTIDES AND USES THEREOF |
| AR044803A1 (es) * | 2003-06-17 | 2005-10-05 | Sembiosys Genetics Inc | Metodos para la produccion de insulina |
| US20070027063A1 (en) * | 2004-01-12 | 2007-02-01 | Mannkind Corporation | Method of preserving the function of insulin-producing cells |
| CA2558835C (en) * | 2004-03-12 | 2011-06-28 | Biodel, Inc. | Rapid acting drug delivery compositions |
| WO2006132530A2 (en) * | 2005-01-31 | 2006-12-14 | Leiden University Medical Center | Methods and means for use in diagnostics and treatment of diabetes |
| CA3193994A1 (en) * | 2020-10-08 | 2022-04-14 | Mary S. MORRIS | Methods and compositions for the treatment and prevention of type 1 diabetes |
-
2020
- 2020-11-25 US US17/778,624 patent/US20230018324A1/en active Pending
- 2020-11-25 CN CN202080084253.5A patent/CN115151273A/zh active Pending
- 2020-11-25 JP JP2022533345A patent/JP2023505190A/ja active Pending
- 2020-11-25 WO PCT/US2020/062159 patent/WO2021113136A1/en unknown
- 2020-11-25 CA CA3159054A patent/CA3159054A1/en active Pending
- 2020-11-25 AU AU2020398147A patent/AU2020398147A1/en active Pending
- 2020-11-25 EP EP20896240.7A patent/EP4069278A4/en active Pending
- 2020-11-27 TW TW109141906A patent/TW202133876A/zh unknown
- 2020-11-30 AR ARP200103323A patent/AR122339A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4069278A4 (en) | 2024-01-10 |
| EP4069278A1 (en) | 2022-10-12 |
| US20230018324A1 (en) | 2023-01-19 |
| CA3159054A1 (en) | 2021-06-10 |
| TW202133876A (zh) | 2021-09-16 |
| JP2023505190A (ja) | 2023-02-08 |
| AU2020398147A1 (en) | 2022-06-02 |
| WO2021113136A1 (en) | 2021-06-10 |
| CN115151273A (zh) | 2022-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020002017A1 (es) | Composición anticonceptiva con efectos cardiovasculares reducidos. | |
| UY37998A (es) | Agentes antivirales contra la hepatitis b | |
| Cheng et al. | Puerarin improves cardiac function through regulation of energy metabolism in Streptozotocin-Nicotinamide induced diabetic mice after myocardial infarction | |
| AR122339A1 (es) | Métodos y composiciones para el tratamiento y la prevención de la diabetes tipo 1 | |
| ES2965283T1 (es) | Tratamiento de pacientes con hemoglobinuria paroxística nocturna mediante un inhibidor del complemento | |
| CO2020012425A2 (es) | Análogos novedosos de glp-1 | |
| CO2022013167A2 (es) | Composiciones y métodos para tratar o prevenir enfermedades inflamatorias que incluyen diabetes mellitus tipo i y tipo ii y enfermedades de la tiroides | |
| MX2021001272A (es) | Composiciones de bismuto-tiol y metodos de uso. | |
| PE20230180A1 (es) | Uso de bi853520 en tratamiento contra el cancer | |
| JP2019534307A5 (es) | ||
| Wiggins-Dohlvik et al. | Melatonin inhibits thermal injury–induced hyperpermeability in microvascular endothelial cells | |
| EA202190776A1 (ru) | Комбинация маломолекулярных ингибиторов cd-47 с другими противораковыми агентами | |
| PE20220593A1 (es) | Composiciones comprimidas de macitentan, metodos y usos de las mismas | |
| AR074108A1 (es) | Metodo para tratar o prevenir la trombosis utilizando etexilato de dabigatran o una sal del mismo con eficacia mejorada sobre la terapia convencional con warfarina | |
| CO2022007006A2 (es) | Vacuna triple contra avibacterium paragallinarum y el virus de la encefalomielitis aviar y el virus de la viruela aviar | |
| AR128257A1 (es) | Compuestos y composiciones para tratar afecciones relacionadas con la actividad de sting | |
| AR115883A1 (es) | Composición farmacéutica para el tratamiento de la adicción a sustancias psicoactivas y/o para la prevención de las recaídas a dicha adicción | |
| AR115722A1 (es) | Método para prevenir o tratar neuropatías periféricas o dolores asociados con enfermedades que tienen neuropatías periféricas o daños astrocíticos | |
| AR106691A1 (es) | Formulaciones oftálmicas de escualamina | |
| CL2021001397A1 (es) | Vibegrón para el tratamiento de los síntomas de la vejiga hiperactiva | |
| Pinelli et al. | Curcumin as a Perspective Protection for Retinal Pigment Epithelium during Autophagy Inhibition in the Course of Retinal Degeneration | |
| ES2135353B1 (es) | Utilizacion del 17beta-estradiol, sus analogos y derivados en el tratamiento de la diabetes mellitus y sus manifestaciones. | |
| AR116878A1 (es) | Vacuna de ibv h52 con proteína espicular heteróloga | |
| AR080048A1 (es) | Tratamiento del tumor del estroma gastrointestinal (gist) con masitinib | |
| WO2007144679A3 (en) | Compounds, kits and methods for conferring cytoprotection |